Vertex Pharma (VRTX) Announces EC Approval for KAFTRIO in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. SPY
2. USO
3. META
4. MSFT
5. MU
6. COST
7. IONS
8. CME
9. AVAV
10. SKHY

Go back to Vertex Pharma (VRTX) Announces EC Approval for KAFTRIO in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older

Vertex Pharma (VRTX) Tops Q1 EPS by 29c, Revenues Beat

April 29, 2021 4:08 PM EDT

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $2.98, $0.29 better than the analyst estimate of $2.69. Revenue for the quarter came in at $1.72 billion versus the consensus estimate of $1.66 billion.

"In CF, our goal is that all eligible patients have access to and can... More